Clinical Progress and Patient Engagement in the Cushing Syndrome and Hypercortisolism Market, Q1 2026

Corcept Therapeutics featured new Korlym clinical data on hyperglycemia secondary to hypercortisolism alongside broader awareness and education efforts.

Crinetics advanced endocrinology engagement through patient storytelling and corporate updates, positioning Atumelnant with Phase 2 data and blockbuster potential.

Sparrow Pharmaceuticals highlighted Clofutriben Phase 2b progress and its novel mechanism in T2D with continued pipeline growth.

Xeris shared patient journey content on YouTube with updates to Recorlev branding on social media.